IL22 and neoplasm: The reduction of tumor growth due to KIR-ESS treatment was even more evident when IL-22 was injected in tumor boundaries, with a final volume of 1.5 ± 0.16 cm3 for KIR-ESS group, and 4.3 ± 0.16 cm3 for vehicle or 3.9 ± 0.16 cm3for Ctrl1 group (p < 0.01; Figure 7A).